BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32326767)

  • 1. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
    Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
    Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Pelster MS; Amaria RN
    Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to use neoadjuvant medical treatment to maximize surgery in melanoma.
    Amaral T; Tampouri I; Garbe C
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):121-130. PubMed ID: 29271674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
    McKean MA; Amaria RN
    Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    Long GV; Menzies AM; Scolyer RA
    J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
    Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Neoadjuvant Therapy in Melanoma.
    Kelly ZR; Gorantla VC; Davar D
    Curr Oncol Rep; 2020 Jun; 22(8):80. PubMed ID: 32601947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
    Olszanski AJ
    J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunotherapy for melanoma.
    Lee AY; Brady MS
    J Surg Oncol; 2021 Mar; 123(3):782-788. PubMed ID: 33002195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.
    Ferraresi V; Vari S
    Hum Vaccin Immunother; 2022 May; 18(3):1971015. PubMed ID: 34882516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Educational Review: Neoadjuvant Approaches to Melanoma.
    Sharon CE; Karakousis GC
    Ann Surg Oncol; 2022 Dec; 29(13):8492-8500. PubMed ID: 35849287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
    Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
    Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Treatments for Advanced Resectable Melanoma.
    Liu JY; Lowe M
    J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Therapy for Melanoma.
    Wada-Ohno M; Ito T; Furue M
    Curr Treat Options Oncol; 2019 Jun; 20(8):63. PubMed ID: 31236710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant immunotherapy for melanoma.
    Thomas D; Bello DM
    J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma.
    McKean MA; Amaria RN
    Am J Clin Dermatol; 2018 Oct; 19(5):639-646. PubMed ID: 30039289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.
    Testori AAE; Ribero S; Indini A; MandalĂ  M
    Am J Clin Dermatol; 2019 Dec; 20(6):817-827. PubMed ID: 31177507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.